Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

QR Code

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching the...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Michael B Horsley, Malik Y Kahook
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2009
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
par: Schmier JK, et autres
Publié: (2014)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
par: Takagi Y, et autres
Publié: (2018)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
par: Jordana K Schmier, et autres
Publié: (2010)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
par: Anne J Lee, et autres
Publié: (2010)

Quality of life of glaucoma patients under medical therapy with different prostaglandins
par: Paletta Guedes RA, et autres
Publié: (2012)

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
par: Oghenowede Eyawo, et autres
Publié: (2009)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
par: Lorenz K, et autres
Publié: (2011)

Challenges in the clinical measurement of ocular surface disease in glaucoma patients
par: Pflugfelder SC, et autres
Publié: (2011)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
par: Tamçelik N, et autres
Publié: (2017)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
par: Hommer A, et autres
Publié: (2011)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
par: Kenji Inoue, et autres
Publié: (2011)

Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid
par: Lawrence Y Ho, et autres
Publié: (2008)

A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma
par: Garcia-Fejioo J, et autres
Publié: (2012)

Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
par: Cvenkel B, et autres
Publié: (2015)

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
par: Fukuda M, et autres
Publié: (2013)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
par: Costa VP, et autres
Publié: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
par: Gregory Katz, et autres
Publié: (2010)

First-year treatment costs among new initiators of topical prostaglandin analogs
par: Jordana K Schmier, et autres
Publié: (2009)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
par: Inoue K, et autres
Publié: (2012)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
par: Ruangvaravate N, et autres
Publié: (2020)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
par: Seibold LK, et autres
Publié: (2014)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
par: Radcliffe NM
Publié: (2014)

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
par: Jordana K Schmier, et autres
Publié: (2010)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
par: Masahiko Ayaki, et autres
Publié: (2010)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
par: Lo JS, et autres
Publié: (2016)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
par: Mizoguchi T, et autres
Publié: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
par: Lanzl I, et autres
Publié: (2013)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
par: Anna Galanopoulos, et autres
Publié: (2008)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
par: Figueiredo BP, et autres
Publié: (2013)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
par: Mylla Boso AL, et autres
Publié: (2020)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
par: Scott D Smid
Publié: (2009)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
par: Inoue K, et autres
Publié: (2012)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
par: Shimizu Y, et autres
Publié: (2015)

Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients
par: Adam M Moss, et autres
Publié: (2010)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
par: Dimitris Papaconstantinou, et autres
Publié: (2009)

Ocular surface disease in posttrabeculectomy/mitomycin C patients
par: Lam J, et autres
Publié: (2015)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
par: Sophia K Mirza, et autres
Publié: (2010)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
par: Pacella F, et autres
Publié: (2012)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
par: Emilio Rintaro Suzuki Jr, et autres
Publié: (2010)

Patient satisfaction with glaucoma therapy: reality or myth?
par: Lemij HG, et autres
Publié: (2015)